AP 158

Drug Profile

AP 158

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Developer United States Army Medical Research Institute of Infectious Diseases
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anthrax; Enterococcal infections; Listeria infections; Staphylococcal infections

Most Recent Events

  • 30 Apr 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
  • 30 Apr 2007 Discontinued - Preclinical for Enterococcal infections in USA (Topical)
  • 30 Apr 2007 Discontinued - Preclinical for Listeria infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top